• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
ZHANG Xiaojiao, ZHANG Hailong, XIANG Youqin, DING Jinsong. Dose dumping of levomilnacipran hydrochloride sustained-release capsules[J]. Journal of China Pharmaceutical University, 2022, 53(1): 60-66. DOI: 10.11665/j.issn.1000-5048.20220109
Citation: ZHANG Xiaojiao, ZHANG Hailong, XIANG Youqin, DING Jinsong. Dose dumping of levomilnacipran hydrochloride sustained-release capsules[J]. Journal of China Pharmaceutical University, 2022, 53(1): 60-66. DOI: 10.11665/j.issn.1000-5048.20220109

Dose dumping of levomilnacipran hydrochloride sustained-release capsules

More Information
  • Received Date: January 31, 2021
  • Revised Date: January 14, 2022
  • In this study, different functional layer formulations and process parameters were used to prepare the levomilnacipran hydrochloride sustained-release capsules, the influence of functional layer formulation and process factors on dose dumping was studied by comparing their release curves in 40% ethanol; and the risk of dose dumping of the self-developed drug was evaluated by the similar factors of the release curve of the self-developed drug and the reference drug.The results showed that as the coating weight increased, the degree of dose dumping decreased; when the concentration of ethanol in the coating liquid solvent was less than 80%, the dose dumping increased; as the atomization pressure and maturation time increase, the dose dumping became more serious. In 0% ethanol (purified water), 5% ethanol, 20% ethanol and 40% ethanol media, the self-developed and reference preparations had the same degree of dose dumping within the specified time, and rotation speed had no significant effect on the release of metformin in vitro. In summary, formulation factors such as coating weight gain, ethanol concentration in the coating solution solvent, and process factors such as atomization pressure and curing time have a serious impact on the dose dumping of sustained-release capsules.Under the optimal functional layer formulation and process, special attention should be paid to the control of risk of self-developed dose dumping.
  • [1]
    .https://fliphtml5.com/zcmg/iwuj.
    [2]
    FDA. Information for healthcare professionals: hydromorphone hydrochloride extended-release capsules(marketed as Palladone)[EB/OL].https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-healthcare-professionals-hydromorphone-hydrochloride-extended-release-capsules-marketed#: ~ :text = Information%20for%20Healthcare%20Professionals%3A%20Hydromorphone%20Hydrochloride%20Extended-Release%20Capsules,0.6-3.4%20%20%200.4-1.5%20%20%200.5-1.9%20.
    [3]
    Murray S,Wooltorton E. Alcohol-associated rapid release of a long-acting opioid[J]. CMAJ,2005,173(7): 756.
    [4]
    Darke AC. Controlled-release opioids and alcohol[J]. CMAJ,2006,174(3):352.
    [5]
    Anand O,Yu LX,Conner DP,et al. Dissolution testing for generic drugs:an FDA perspective[J]. AAPS J,2011,13(3):328-335.
    [6]
    PMDA.Regarding concepts on bioequivalence test of production change of oral solid preparation[EB].[2013-04-19].http://www.pmda.go.jp/files/000157176.pdf#page = 16.
    [7]
    FDA.Levomilnacipran[EB/OL].[2013-07-25https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204168s000lbl.pdf
    [8]
    Hair P,Cameron F,Garnock-Jones KP. Levomilnacipran extended release:first global approval[J]. Drugs,2013,73(14):1639-1645.
    [9]
    He S,Yang XM,Li HF. New antidepressant:levomilnacipran[J].Chin J New Drugs Clin Med(中国新药与临床杂志),2015,34(6):418-422.
    [10]
    Surana R,Divi M,Chhettry A. Stable dosage forms of levomilnacipran:
    US8481598[P]. 2013-07-09.
    [11]
    Narisawa S,Yoshino H,Hirakawa Y,et al. Porosity-controlled ethylcellulose film coating. I. formation of porous ethylcellulose film in the casting process and factors affecting film-density[J]. Chem Pharm Bull,1993,41(2):329-334.
  • Cited by

    Periodical cited type(5)

    1. 刘梦婷,孙国祥. 格列齐特缓释片的剂量倾泻研究. 中国医药工业杂志. 2024(04): 565-570 .
    2. 周培培,孙春艳,侯晓虹. 雷诺嗪缓释片剂量倾泻方法学建立与验证. 沈阳药科大学学报. 2024(12): 1627-1633 .
    3. 刘新颖,许向阳,曾令高,毛文星,郑冬梅,高梓真. 盐酸羟考酮缓释片体外释药特性研究. 中国药业. 2023(16): 52-56 .
    4. 苗国力,郭洪涛,刘文玲,崔芹芹. 盐酸文拉法辛缓释胶囊的制备及释放度研究. 山东化工. 2023(17): 48-53 .
    5. 徐晓宏,陶铭,李飞,魏群,龚青. 缓控释微丸胶囊仿制药处方工艺研究的审评考虑. 现代药物与临床. 2023(12): 3139-3144 .

    Other cited types(0)

Catalog

    Article views (209) PDF downloads (429) Cited by(5)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return